Antibody Therapeutic Development & Commercialization
BioTechLogic’s team of experts has deep expertise and experience working on the front lines of antibody therapeutic development.
The development of a successful antibody-based therapeutic requires the identification and creation of a selective and potent molecule that performs the needed action, humanization of sequences, affinity maturation, engineering to modulate effector functions, and addressing biophysical challenges that would negatively impact manufacturability and/or patient effectiveness.
Complete Antibody Therapy Product Lifecycle Support Services
BioTechLogic has extensive experience with antibody therapy development and commercialization, from preclinical to market. Whether choosing an antibody with the desired affinity and specificity for an antigen target, engineering an antibody to do the job, or selecting the appropriate expression system, we are here to help.
Antibody Development & Production
BioTechLogic has extensive experience supporting the development and production of monoclonal antibodies (mAbs), bispecific antibodies, antibody fragments, radiolabeled antibodies, antibody conjugates (ADC’s), and more.
How BioTechLogic Can Help
-
- Expression system selection
- Product characterization
- Analytical method development
- CDMO selection
-
- Critical Quality Attributes understanding
- Purification processes
- Reproducibility
- ADC conjugation development / optimization
-
- Upstream process development and scale-up
- Downstream process development and scale-up
- Regulatory filing support
Antibody Therapeutics CMC Services
CMC Strategy
Quality Assurance
Analytical Services
Regulatory Consulting & Submissions Support
Process Development & Validation
Contract Services & Tech Transfer Support
Supply Chain Management
Inspection Readiness
Project Management
Years
Consultants
Clients
projects
Antibody Therapeutic Resources
How the Industry’s Pandemic Response Opened the Door to Therapeutic Opportunities
The biopharma industry was certainly not immune to the turbulence brought about by the COVID-19 pandemic. The pandemic disrupted — and in some cases, stopped completely — clinical trials around the globe. In fact, as of January 2021, more than 2,000 clinical trials...
Lessons and Insights into the Korean Biopharmaceutical Market During the COVID-19 Pandemic
Tonia Becker, Life Sciences Editor, Macon Raine talks with BioTechLogic's Dr. Eileen Choi How is the COVID-19 pandemic affecting the global biopharmaceutical market? To get at least some perspective on this question, there is no better place to turn to than...
Biopharmaceutical Developers Tackle COVID-19 Pandemic-Inflicted Challenges
Tonia Becker, Life Sciences Editor, Macon Raine, talks with BioTechLogic's Dr. Mike Berry. Knowing that BioTechLogic’s team of biopharmaceutical consultants is working with many companies in the industry to help speed the path to market, I was interested in learning...
mAbs and Their Therapeutic Evolution
WHITE PAPER mAbs and Their Therapeutic EvolutionBy Tracy TreDenick, Head of Regulatory and Quality, and Senior Consultant Monoclonal antibodies (mAbs) elegant specificity has catapulted them to a starring role within the world of precision medicine over the course of...
The Evolution of Therapeutic Monoclonal Antibodies
By Tracy TreDenick, Head of Regulatory and Quality, and Senior Consultant, BioTechLogic The elegant simplicity of monoclonal antibodies (mAbs) has catapulted them to a starring role within the world of precision medicine over the course of the last couple of decades....
